US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
TW432073B
(en)
*
|
1995-12-28 |
2001-05-01 |
Pfizer |
Pyrazolopyridine compounds
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
NZ334148A
(en)
*
|
1996-08-12 |
2001-12-21 |
Celgene Corp |
3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6699899B1
(en)
*
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
CN1420776A
(zh)
*
|
2000-03-31 |
2003-05-28 |
塞尔基因公司 |
环氧合酶-2活性的抑制
|
US8030343B2
(en)
*
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
ES2290091T3
(es)
*
|
2000-11-30 |
2008-02-16 |
The Children's Medical Center Corporation |
Sintesis de enantiomeros de 4-amino-talidomida.
|
US7091353B2
(en)
*
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
US7491634B2
(en)
*
|
2006-04-28 |
2009-02-17 |
Asm International N.V. |
Methods for forming roughened surfaces and applications thereof
|
CN1965823B
(zh)
*
|
2002-03-20 |
2010-05-12 |
细胞基因公司 |
(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲磺酰基乙基]-4-乙酰氨基异吲哚啉-1,3-二酮、其合成方法及其组合物
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
WO2003080048A1
(en)
*
|
2002-03-20 |
2003-10-02 |
Celgene Corporation |
(-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7276529B2
(en)
*
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7208516B2
(en)
*
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7893101B2
(en)
*
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7498171B2
(en)
*
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
CA2481385A1
(en)
*
|
2002-04-12 |
2003-10-23 |
Celgene Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US20050148034A1
(en)
*
|
2002-04-12 |
2005-07-07 |
Hariri Robert J. |
Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
EP2915533B1
(de)
*
|
2002-05-17 |
2017-09-13 |
Celgene Corporation |
Pharmazeutische Zusammensetzungen zur Behandlung von Krebs
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
EP1556033A4
(de)
*
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
|
US20060148848A1
(en)
*
|
2002-07-02 |
2006-07-06 |
Qlt, Inc. |
Compounds and methods for treating cancer and inflammation
|
AU2003228509B2
(en)
*
|
2002-10-15 |
2008-06-26 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
AU2003285107B2
(en)
*
|
2002-10-31 |
2008-01-10 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
BR0316057A
(pt)
|
2002-11-06 |
2005-09-20 |
Celgene Corp |
Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
|
AU2003226361B2
(en)
*
|
2002-11-06 |
2009-01-22 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
|
CN1738613A
(zh)
*
|
2002-11-18 |
2006-02-22 |
细胞基因公司 |
包含(+)-3-(3,4-二甲氧基-苯基)-3-(1-氧代-1,3-二氢-异吲哚-2-基)-丙酰胺的组合物及其使用方法
|
MXPA05005161A
(es)
*
|
2002-11-18 |
2005-07-22 |
Celgene Corp |
Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
|
CN1802353A
(zh)
*
|
2002-12-30 |
2006-07-12 |
细胞基因公司 |
氟烷氧基取代的1,3-二氢-异吲哚化合物及其药物用途
|
WO2004078176A1
(en)
*
|
2003-03-03 |
2004-09-16 |
F. Hoffmann-La Roche Ag |
2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators
|
US20040175382A1
(en)
*
|
2003-03-06 |
2004-09-09 |
Schafer Peter H. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
EP1605935A4
(de)
*
|
2003-03-06 |
2009-05-20 |
Celgene Corp |
Verfahren zur verwendung von und zusammensetzungen mit selektiven zyotkin-hemmenden arzneimitteln zur behandlung und versorgung von erkrankungen des zentralen nervensystems
|
ES2436606T3
(es)
*
|
2003-03-12 |
2014-01-03 |
Celgene Corporation |
Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos
|
WO2005000406A2
(en)
*
|
2003-06-23 |
2005-01-06 |
Neurochem (International) Limited |
Treatment of amyloid- and epileptogenesis-associated diseases
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
CA2543132A1
(en)
*
|
2003-10-23 |
2005-05-19 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20050142104A1
(en)
*
|
2003-11-06 |
2005-06-30 |
Zeldis Jerome B. |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
|
CN1901911A
(zh)
*
|
2003-11-06 |
2007-01-24 |
细胞基因公司 |
使用沙利度胺治疗和控制癌症和其它疾病的组合物和方法
|
NZ547689A
(en)
|
2003-11-19 |
2009-05-31 |
Signal Pharm Llc |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
EP1694328A4
(de)
*
|
2003-12-02 |
2010-02-17 |
Celgene Corp |
Verfahren und zusammensetzungen zur behandlung und versorgung von hämoglobinopathie und anämie
|
EP1744749A4
(de)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen
|
CA2563207A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
WO2005102317A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Celgene Corporation |
Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
|
US20090010886A1
(en)
*
|
2004-05-05 |
2009-01-08 |
Celgene Corporation |
Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione
|
US7244759B2
(en)
*
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
EP1811992A2
(de)
*
|
2004-10-28 |
2007-08-01 |
Celgene Corporation |
Verfahren und zusammensetzungen unter verwendung von pde4-modulatoren zur behandlung und versorgung von verletzungen des zentralen nervensystems
|
WO2006065814A1
(en)
*
|
2004-12-13 |
2006-06-22 |
Celgene Corporation |
Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
TW200804347A
(en)
*
|
2006-01-10 |
2008-01-16 |
Janssen Pharmaceutica Nv |
Urotensin II receptor antagonists
|
AU2007281591A1
(en)
|
2006-07-31 |
2008-02-07 |
Janssen Pharmaceutica, N.V. |
Urotensin II receptor antagonists
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
PA8782701A1
(es)
*
|
2007-06-07 |
2009-01-23 |
Janssen Pharmaceutica Nv |
Antagonistas del receptor de urotensina ii
|
WO2009020590A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
MX2010010334A
(es)
*
|
2008-03-24 |
2010-10-08 |
Celgene Corp |
Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
|
KR20140142323A
(ko)
|
2008-03-27 |
2014-12-11 |
셀진 코포레이션 |
(+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
|
EP2687213B1
(de)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion umfassende feste Formen, Zusammensetzungen daraus und ihre Verwendungszwecke
|
EP2326644B1
(de)
*
|
2008-08-02 |
2012-02-22 |
Janssen Pharmaceutica N.V. |
Urotensin-ii-rezeptorantagonisten
|
CA2736171A1
(en)
*
|
2008-09-10 |
2010-03-18 |
Celgene Corporation |
Processes for the preparation of aminosulfone compounds
|
CA2750123A1
(en)
|
2009-02-10 |
2010-08-19 |
Celgene Corporation |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
WO2010130224A1
(zh)
*
|
2009-05-14 |
2010-11-18 |
天津和美生物技术有限公司 |
噻吩衍生物
|
ME01883B
(me)
*
|
2009-06-18 |
2014-12-20 |
Concert Pharmaceuticals Inc |
Deuterijumski derivati izoindolin-1,3-diona kao inhibitori pde4 i tnf-alfa
|
MY183201A
(en)
|
2009-10-09 |
2021-02-18 |
Celgene Corp |
Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
US20110318741A1
(en)
|
2010-06-15 |
2011-12-29 |
Schafer Peter H |
Biomarkers for the treatment of psoriasis
|
WO2012083153A1
(en)
*
|
2010-12-16 |
2012-06-21 |
Nektar Therapeutics |
Oligomer-containing apremilast moiety compounds
|
CN102558022B
(zh)
*
|
2010-12-22 |
2016-06-15 |
康塞特医药品有限公司 |
取代的异吲哚啉-1,3二酮衍生物
|
EP2663549B1
(de)
|
2011-01-10 |
2018-03-14 |
Celgene Corporation |
Phenethylsulfonisoindolinderivate als pde-4- und/oder zytokin-hemmer
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
EP2683376B1
(de)
|
2011-03-07 |
2018-11-28 |
Celgene Corporation |
Verfahren zur behandlung von erkrankungen mit isoindolinverbindungen
|
CN103635188B
(zh)
|
2011-04-28 |
2017-03-22 |
细胞基因公司 |
使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物
|
PL2797581T3
(pl)
*
|
2011-12-27 |
2020-10-05 |
Amgen (Europe) GmbH |
Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu
|
AR090100A1
(es)
|
2012-02-21 |
2014-10-22 |
Celgene Corp |
Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
|
EP2730278A1
(de)
|
2012-11-08 |
2014-05-14 |
Ratiopharm GmbH |
Zusammensetzungsschmelze
|
US9872854B2
(en)
|
2013-03-14 |
2018-01-23 |
Celgene Corporation |
Methods for the treatment of psoriatic arthritis using apremilast
|
EP3010490A1
(de)
|
2013-06-17 |
2016-04-27 |
Celgene Corporation |
Tablettenformulierungen aus (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion
|
IN2014MU01283A
(de)
|
2014-04-04 |
2015-10-09 |
Cadila Healthcare Ltd |
|
WO2015173792A1
(en)
|
2014-05-11 |
2015-11-19 |
Mapi Pharma Ltd. |
Amorphous form of apremilast
|
US9480676B2
(en)
|
2014-05-15 |
2016-11-01 |
Celgene Corporation |
Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
EP3142663A1
(de)
|
2014-05-16 |
2017-03-22 |
Celgene Corporation |
Zusammensetzungen und verfahren zur behandlung von arteriosklerotischen herz-kreislauf-erkrankungen mit pde4-modulatoren
|
EP2949645A1
(de)
|
2014-05-28 |
2015-12-02 |
LEK Pharmaceuticals d.d. |
Verfahren zur Herstellung von ß-Aminosulfonverbindungen
|
EP3157520B1
(de)
|
2014-06-23 |
2019-09-04 |
Celgene Corporation |
Apremilast zur behandlung einer lebererkrankung oder leberfunktionsanomalie
|
WO2016025686A1
(en)
|
2014-08-15 |
2016-02-18 |
Celgene Corporation |
Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
|
PL3182996T3
(pl)
|
2014-08-22 |
2023-04-17 |
Celgene Corporation |
Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
|
CN105461610B
(zh)
*
|
2014-09-10 |
2018-04-13 |
杭州普晒医药科技有限公司 |
一种阿普斯特的晶型及其制备方法、药物组合物和用途
|
CN104761484B
(zh)
*
|
2014-11-24 |
2018-03-27 |
上海优拓医药科技有限公司 |
一种稳定的不含溶剂化物的阿普司特晶型ii及其制备方法
|
CN104496886A
(zh)
*
|
2014-12-11 |
2015-04-08 |
杭州新博思生物医药有限公司 |
一种高纯度阿普斯特b晶型的制备方法
|
US10287248B2
(en)
|
2015-03-19 |
2019-05-14 |
Cipla Limited |
Process for the preparation of apremilast
|
EP3280701B1
(de)
|
2015-04-09 |
2019-10-16 |
Zentiva K.S. |
Verfahren zur chiralen auflösung des schlüsselintermediats der synthese von apremilast und dessen verwendung zur herstellung von reinem apremilast
|
EP3286168A1
(de)
|
2015-04-24 |
2018-02-28 |
Zentiva K.S. |
Feste form von apremilast und verfahren zu ihrer herstellung
|
US10370329B2
(en)
*
|
2015-04-27 |
2019-08-06 |
Mylan Laboratories Limited |
Process for the enantiomeric resolution of apremilast intermediates
|
CN104945306B
(zh)
*
|
2015-05-25 |
2017-07-21 |
山东铭康医药技术有限公司 |
制备光学纯阿普斯特的方法
|
CZ2015383A3
(cs)
|
2015-06-05 |
2016-12-14 |
Zentiva, K.S. |
Způsob přípravy klíčového intermediátu apremilastu, využívající enzymatické štěpení racemických aminů
|
EP3106457A1
(de)
|
2015-06-15 |
2016-12-21 |
LEK Pharmaceuticals d.d. |
Neuartiger synthetischer pfad zu apremilast
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
EP3144393A1
(de)
|
2015-09-18 |
2017-03-22 |
LEK Pharmaceuticals d.d. |
Synthetischer pfad zu apremilast
|
EP3356327A1
(de)
|
2015-09-29 |
2018-08-08 |
Pliva Hrvatska D.O.O. |
Verfahren zur herstellung von apremilast und zwischenprodukten davon
|
WO2017070291A1
(en)
|
2015-10-21 |
2017-04-27 |
Celgene Corporation |
Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
|
WO2017085568A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Alembic Pharmaceuticals Limited |
An improved process and novel polymorphic form of apremilast
|
CN105294533A
(zh)
*
|
2015-12-02 |
2016-02-03 |
宋彤云 |
一种治疗骨病的药物组合物
|
WO2017179065A1
(en)
|
2016-04-15 |
2017-10-19 |
Davuluri Ramamohan Rao |
Improved process for the preparation of apremilast
|
EP3471698A1
(de)
|
2016-06-15 |
2019-04-24 |
Torrent Pharmaceuticals Limited |
Topische zusammensetzungen von apremilast
|
US10196355B2
(en)
|
2016-06-20 |
2019-02-05 |
Johnson Matthey Public Limited Company |
Forms of apremilast
|
CN106543050B
(zh)
*
|
2016-09-28 |
2018-04-10 |
中南大学湘雅医院 |
一种阿普斯特中间体的合成工艺
|
AU2018228541B2
(en)
*
|
2017-02-28 |
2020-07-16 |
Kangpu Biopharmaceuticals, Ltd. |
Novel isoindoline derivative, and pharmaceutical composition and application thereof
|
EP3606908B1
(de)
*
|
2017-04-04 |
2020-06-17 |
Quimica Sintetica, S.A. |
Spaltung von racemischen beta-aminosulfon-verbindungen
|
US10689332B2
(en)
|
2017-04-04 |
2020-06-23 |
Quimica Sintetica, S.A. |
Racemic beta-aminosulfone compounds
|
WO2018203192A1
(en)
|
2017-05-04 |
2018-11-08 |
Unichem Laboratories Ltd |
Novel process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4-yl]acetamide
|
CN109422671B
(zh)
*
|
2017-08-31 |
2022-06-07 |
重庆医药工业研究院有限责任公司 |
一种阿普斯特中间体的制备方法
|
JP2020533383A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌の組合せ治療
|
CA3079299A1
(en)
|
2017-10-23 |
2019-05-02 |
Boehringer Ingelheim International Gmbh |
New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
|
WO2019142124A1
(en)
|
2018-01-17 |
2019-07-25 |
Cadila Healthcare Limited |
Pharmaceutical compositions for treatment of vitiligo
|
CA3099072A1
(en)
*
|
2018-05-02 |
2019-11-07 |
Tianjin Hemay Pharmaceutical Co., Ltd. |
Solid forms of thiophene derivatives
|
WO2020020101A1
(zh)
*
|
2018-07-22 |
2020-01-30 |
上海星叶医药科技有限公司 |
苯并异硒唑酮胺类化合物及其制备方法和用途
|
CN110423213B
(zh)
*
|
2019-08-22 |
2021-06-04 |
上海英诺富成生物科技有限公司 |
一种阿普斯特衍生物及其制备方法与应用
|
EP3929179A1
(de)
|
2020-06-22 |
2021-12-29 |
Biohorm, S.L. |
Entzündungshemmende verbindungen und verfahren zu deren herstellung
|
CN114790164B
(zh)
|
2021-08-13 |
2022-12-27 |
苏州璞正医药有限公司 |
一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
|